Peter Ordentlich, Ph.D. co-founded Syndax Pharmaceuticals in October 2005 and has served as Chief Scientific Officer since September 2016. Dr. Ordentlich previously served as our Syndax Chief Technical Officer from November 2013 to August 2016, Vice President, Translational Medicine from January 2012 to October 2013, Executive Director, Translational Science from January 2011 to December 2011, and Director, Scientific Affairs and Strategic Alliances from January 2008 to December 2010. Prior to founding Syndax, Dr. Ordentlich was a scientist at the Salk Institute for Biological Studies, a biological research non-profit organization. He also spent five years as a research scientist at X-Ceptor Therapeutics, Inc., a drug discovery company, which was acquired by Exelixis, Inc. Dr. Ordentlich received a B.A. in Biochemistry and a Ph.D. in Immunology from the University of Pennsylvania.
Board of Directors